Skip to main content

Sorrento Therapeutics, Inc. (SRNE)

NASDAQ: SRNE · IEX Real-Time Price · USD
5.97 0.72 (13.71%)
Dec 7, 2021 3:35 PM EST - Market open
Market Cap1.83B
Revenue (ttm)51.33M
Net Income (ttm)-355.41M
Shares Out306.34M
EPS (ttm)-1.25
PE Ration/a
Forward PE3.55
Dividendn/a
Ex-Dividend Daten/a
Volume8,182,651
Open5.35
Previous Close5.25
Day's Range5.35 - 6.14
52-Week Range4.69 - 17.25
Beta2.25
AnalystsBuy
Price Target26.67 (+346.7%)
Earnings DateNov 12, 2021

About SRNE

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody appr...

IndustryBiotechnology
Founded2006
CEOHenry Ji
Employees502
Stock ExchangeNASDAQ
Ticker SymbolSRNE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SRNE stock is "Buy" and the 12-month stock price forecast is 26.67.

Price Target
$26.67
(346.73% upside)
Analyst Consensus: Buy

News

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthr...

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA)...

1 hour ago - GlobeNewsWire

Sorrento Therapeutics' Clinical Laboratory Receives Accreditation From the College of American Pathologists

Sorrento has received accreditation from the American College of Pathologists, which allows Sorrento to bill to Medicare and Medicaid Sorrento has received accreditation from the American College of Pat...

6 hours ago - GlobeNewsWire

Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil

SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that initial loading orders have been processed and scheduled for delivery later this ...

1 day ago - GlobeNewsWire

Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) E...

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I, a Cayman Isla...

1 day ago - GlobeNewsWire

Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatmen...

SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with pot...

2 days ago - GlobeNewsWire

Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming confe...

1 week ago - GlobeNewsWire

Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 an...

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Can...

1 week ago - GlobeNewsWire

Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market

SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract ...

2 weeks ago - GlobeNewsWire

Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention...

SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento's COVI-STIX COVID-1...

3 weeks ago - GlobeNewsWire

Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-...

SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the peer-reviewed publication of significant results from a pivotal study of abivertin...

3 weeks ago - GlobeNewsWire

Sorrento Awarded California Competes Tax Credit

SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes...

1 month ago - GlobeNewsWire

Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detectio...

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of approval from the Brazilian regulatory agency (ANVISA) for COVISTIX in Brazil.

1 month ago - GlobeNewsWire

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021

Biotech stocks to note as the coronavirus pandemic rages on across the globe.

Other symbols:ABVCANIPMRNASNY
1 month ago - Stockmarketcom

Sorrento's License Partner, Lee's Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Soca...

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee's Ph...

1 month ago - GlobeNewsWire

Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

UPDATE  – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalize...

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from two Phase 2 studies designed to identify the hospita...

1 month ago - GlobeNewsWire

Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe C...

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from two Phase 2 studies designed to identify the hospita...

1 month ago - GlobeNewsWire

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registrati...

SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA...

1 month ago - GlobeNewsWire

Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) f...

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") previously announced that its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento's subsid...

1 month ago - GlobeNewsWire

FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable...

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the company has received FDA clearance to proceed with a global Phase 2 clinical study ...

1 month ago - GlobeNewsWire

Dear SRNE Stock Fans, Here's the Latest Patent News to Watch

Despite some relatively bullish news that came out yesterday, investors in vaccine stocks such as SRNE stock are in sell mode today. The post Dear SRNE Stock Fans, Here's the Latest Patent News to Watch...

2 months ago - InvestorPlace

CORRECTION - Sorrento Therapeutics, Inc.

SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- In a release issued on Tuesday, September 28th by Sorrento Therapeutics, Inc. (NASDAQ: SRNE), please note that the date of the conference has been corrected...

2 months ago - GlobeNewsWire

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on Septemb...

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Virtual Healthcare Conference.

2 months ago - GlobeNewsWire

Skip the Bullsh*t! CEO Speak Reveals 2 Reddit Stock Gems

Are Redditors Being Fooled By Corporate Showmanship? “If you can't dazzle them with brilliance, baffle them with bullsh*t.

Other symbols:MRNA
2 months ago - InvestorPlace

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Vi...

SAN DIEGO, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, ...

2 months ago - GlobeNewsWire